spironolactone has been researched along with Atherogenesis in 14 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The beneficial effects of eplerenone, a specific mineralocorticoid receptor blocker, were previously demonstrated in early atherosclerosis (ATS)." | 7.78 | Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. ( Coleman, R; Gamliel-Lazarovich, A; Keidar, S; Raz-Pasteur, A, 2012) |
| "En face analysis revealed that eplerenone treatment was unable to attenuate atherosclerosis as assessed by percentage lesion area quantitation in the aortae of these mice compared with untreated diabetic mice (diabetic, 10." | 7.75 | Eplerenone does not attenuate diabetes-associated atherosclerosis. ( Allen, TJ; Cooper, ME; Koh, PJ; Koitka, A, 2009) |
| "These results suggest that aldosterone may play a critical role in atherogenesis subsequent to oxidative stress in part independent of angiotensin II-mediated signaling, and that eplerenone could prevent atherosclerosis by attenuating oxidative stress and inflammation." | 7.73 | Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. ( Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T, 2006) |
| "Eplerenone treatment of patients with PA reduces blood pressure, increases serum potassium level, and improves vascular status." | 5.43 | Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism. ( Anzai, K; Kawate, H; Matsuda, Y; Matsuzaki, C; Nomura, M; Ohnaka, K; Sakamoto, R; Shibue, K; Takayanagi, R, 2016) |
| "The beneficial effects of eplerenone, a specific mineralocorticoid receptor blocker, were previously demonstrated in early atherosclerosis (ATS)." | 3.78 | Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice. ( Coleman, R; Gamliel-Lazarovich, A; Keidar, S; Raz-Pasteur, A, 2012) |
| "En face analysis revealed that eplerenone treatment was unable to attenuate atherosclerosis as assessed by percentage lesion area quantitation in the aortae of these mice compared with untreated diabetic mice (diabetic, 10." | 3.75 | Eplerenone does not attenuate diabetes-associated atherosclerosis. ( Allen, TJ; Cooper, ME; Koh, PJ; Koitka, A, 2009) |
| "These results suggest that aldosterone may play a critical role in atherogenesis subsequent to oxidative stress in part independent of angiotensin II-mediated signaling, and that eplerenone could prevent atherosclerosis by attenuating oxidative stress and inflammation." | 3.73 | Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. ( Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T, 2006) |
| "Eplerenone treatment of patients with PA reduces blood pressure, increases serum potassium level, and improves vascular status." | 1.43 | Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism. ( Anzai, K; Kawate, H; Matsuda, Y; Matsuzaki, C; Nomura, M; Ohnaka, K; Sakamoto, R; Shibue, K; Takayanagi, R, 2016) |
| "Chronic inflammation in ankylosing spondylitis (AS) is associated with vascular endothelial dysfunction which leads to accelerated atherosclerosis." | 1.39 | Spironolactone improves endothelial dysfunction in ankylosing spondylitis. ( Garg, N; Kaur, L; Khichi, D; Syngle, A; Verma, I; Vohra, K, 2013) |
| " We investigated the effect of a combination of eplerenone, a selective aldosterone antagonist, and enalapril, an angiotensin-converting enzyme inhibitor, on NO bioavailability and spontaneous atherosclerotic changes." | 1.35 | Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. ( Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Tsujioka, H; Yoshida, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Man, JJ | 1 |
| Lu, Q | 1 |
| Moss, ME | 1 |
| Carvajal, B | 1 |
| Baur, W | 1 |
| Garza, AE | 1 |
| Freeman, R | 1 |
| Anastasiou, M | 1 |
| Ngwenyama, N | 1 |
| Adler, GK | 1 |
| Alcaide, P | 1 |
| Jaffe, IZ | 2 |
| Rajagopalan, S | 1 |
| Alaiti, MA | 1 |
| Broadwater, K | 1 |
| Goud, A | 1 |
| Gaztanaga, J | 1 |
| Connelly, K | 1 |
| Fares, A | 1 |
| Shirazian, S | 1 |
| Kreatsoulas, C | 1 |
| Farkouh, M | 1 |
| Dobre, M | 1 |
| Fink, JC | 1 |
| Weir, MR | 1 |
| Syngle, A | 1 |
| Vohra, K | 1 |
| Khichi, D | 1 |
| Garg, N | 1 |
| Verma, I | 1 |
| Kaur, L | 1 |
| Matsuda, Y | 1 |
| Kawate, H | 1 |
| Matsuzaki, C | 1 |
| Sakamoto, R | 1 |
| Shibue, K | 1 |
| Ohnaka, K | 1 |
| Anzai, K | 1 |
| Nomura, M | 1 |
| Takayanagi, R | 1 |
| Koh, PJ | 1 |
| Koitka, A | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| Martinez, FA | 1 |
| Deuchar, GA | 1 |
| McLean, D | 1 |
| Hadoke, PWF | 1 |
| Brownstein, DG | 1 |
| Webb, DJ | 1 |
| Mullins, JJ | 1 |
| Chapman, K | 1 |
| Seckl, JR | 1 |
| Kotelevtsev, YV | 1 |
| Newfell, BG | 1 |
| Iyer, LK | 1 |
| Mohammad, NN | 1 |
| McGraw, AP | 1 |
| Ehsan, A | 1 |
| Rosano, G | 1 |
| Huang, PL | 1 |
| Mendelsohn, ME | 1 |
| Raz-Pasteur, A | 2 |
| Gamliel-Lazarovich, A | 2 |
| Gantman, A | 1 |
| Coleman, R | 2 |
| Keidar, S | 2 |
| Takai, S | 1 |
| Jin, D | 1 |
| Muramatsu, M | 1 |
| Kirimura, K | 1 |
| Sakonjo, H | 1 |
| Miyazaki, M | 1 |
| Strawn, WB | 1 |
| Suzuki, J | 1 |
| Iwai, M | 1 |
| Mogi, M | 1 |
| Oshita, A | 1 |
| Yoshii, T | 1 |
| Higaki, J | 1 |
| Horiuchi, M | 1 |
| Imanishi, T | 1 |
| Ikejima, H | 1 |
| Tsujioka, H | 1 |
| Kuroi, A | 1 |
| Kobayashi, K | 1 |
| Muragaki, Y | 1 |
| Mochizuki, S | 1 |
| Goto, M | 1 |
| Yoshida, K | 1 |
| Akasaka, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cardiometabolic Effects of Eplerenone in HIV Infection[NCT02629094] | Phase 2 | 5 participants (Actual) | Interventional | 2015-12-02 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in intraventricular septum percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline intraventicular septum percentage value of lipid from the week 24 intraventicular septum percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks
| Intervention | percentage of lipid (Mean) |
|---|---|
| Eplerenone | -0.33 |
Mean change in hepatic percentage of lipid by MR spectroscopy. This was calculated by subtracting the baseline hepatic percentage value of lipid from the week 24 hepatic percentage value of lipid by MR spectroscopy. (NCT02629094)
Timeframe: 24 weeks
| Intervention | percentage of lipid (Mean) |
|---|---|
| Eplerenone | 13 |
1 trial available for spironolactone and Atherogenesis
| Article | Year |
|---|---|
Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial.
Topics: Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Clinical Protocols; Diabetes Mellitus, Type 2; Di | 2017 |
13 other studies available for spironolactone and Atherogenesis
| Article | Year |
|---|---|
Myeloid Mineralocorticoid Receptor Transcriptionally Regulates P-Selectin Glycoprotein Ligand-1 and Promotes Monocyte Trafficking and Atherosclerosis.
Topics: Adult; Animals; Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Cell Adhesion; Disease Models, An | 2021 |
Spironolactone improves endothelial dysfunction in ankylosing spondylitis.
Topics: Adolescent; Adult; Atherosclerosis; Blood Sedimentation; Brachial Artery; C-Reactive Protein; Diuret | 2013 |
Eplerenone improves carotid intima-media thickness (IMT) in patients with primary aldosteronism.
Topics: Adrenalectomy; Adult; Aged; Aldosterone; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness | 2016 |
Eplerenone does not attenuate diabetes-associated atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Diabetes Mellitus, Experimental; Enzyme | 2009 |
Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
Topics: Aldosterone; Atherosclerosis; Blood Vessels; Cardiomegaly; Cardiotonic Agents; Endothelium; Heart Fa | 2010 |
11β-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Amiloride; Animals; Aorta; Apolipoproteins E; Atheroscl | 2011 |
Aldosterone regulates vascular gene transcription via oxidative stress-dependent and -independent pathways.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Cells, Cultured; Dactinomycin; Endothelium, Vascular; | 2011 |
Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice.
Topics: Aldosterone; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Biomarkers; Diet, Sodium-Restricted | 2014 |
Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cytochrome P-450 CYP1 | 2012 |
Eplerenone inhibits atherosclerosis in nonhuman primates.
Topics: Acetylcholine; Animals; Aorta; Atherosclerosis; Carotid Arteries; Chemokine CCL2; Cholesterol, Dieta | 2005 |
Eplerenone antagonizes atherosclerosis, but what is the agonist?
Topics: Aldosterone; Animals; Atherosclerosis; Eplerenone; Humans; Mineralocorticoid Receptor Antagonists; R | 2005 |
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Chole | 2006 |
Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability.
Topics: Acetylcholine; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Athe | 2008 |